Investing

Top Day Trader Alerts (BP, CRIS, FDX, NBIX, NOK, SMTS, SONC, URRE)

There are many stocks on the move this morning in the top day trader alerts and top active trader alerts.  BP plc (NYSE: BP), Curis Inc. (NASDAQ: CRIS), FedEx Corporation (NYSE: FDX), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Nokia Corporation (NYSE: NOK), Somanetics Corp. (NASDAQ: SMTS), Sonic Corp. (NASDAQ: SONC), and Uranium Resources, Inc. (NASDAQ: URRE) are all on the move this morning.  We have compiled news, reactions, historical data, and relative color where applicable.

BP plc (NYSE: BP) is down again as the saga continues.  Fitch cut it sharply, its dividend is at risk, demands are being made for endless reimbursements and damages, and its CEO is supposed to meet with the White House.  Shares are down 4% at $30.15 on over 4 million ADR shares trading in the pre-market.

Curis Inc. (NASDAQ: CRIS) is getting spanked, and not lightly.  Its mid-stage colon cancer drug failed to show benefits as a first-line treatment in metastatic colorectal cancer.  Shares are down a sharp 39% at $1.98 versus a 52-week range of $1.28 to $3.70.

FedEx Corporation (NYSE: FDX) is trading lower despite earnings returning to strong profits.  The guidance for Fiscal May-2011 was offered as being $4.40 to $5.00 EPS versus Thomson Reuters estimates of $5.06 EPS.  Shares are down 2% at $81.47 on 200,000 shares.

Neurocrine Biosciences Inc. (NASDAQ: NBIX) is surging as it has a big deal on its hands with much larger Abbott Laboratories (NYSE: ABT).  Abbott has agreed to pay as much as $575 million to help develop and commercialize Neurocrine’s endometriosis treatment. Shares are up over 20% at $5.67 on 375,000 shares, a new 52-week high as the prior range was $1.94 to $5.20.

Nokia Corporation (NYSE: NOK) is getting hammered and is hitting 52-week lows on the ADR.  All the smartphone sales are beating out Nokia it appears as it lowered its devices and services for its second quarter 2010 outlook…. Shares are down 9.8% at $8.86 on over 15 million shares in pre-market trading.  The prior 52-week range was $9.10 to $16.00.

Somanetics Corp. (NASDAQ: SMTS) is surging on news that it is being acquired.  Covidien plc (NYSE: COV) announced a signed definitive merger agreement to acquire all of the outstanding shares of Somanetics Corporation for $25.00 per share in cash.  The total comes to $250 million, net of cash acquired. Somanetics is up over 31% at $24.87 on almost 2 million shares in the pre-market.  The prior 52-week range was $12.90 to $21.96.

Sonic Corp. (NASDAQ: SONC) lowered guidance… again.  Investors are going to probably going to get more than frustrated here if this happens again.  Shares are down 3% at $9.58 versus a 52-week range of $8.07 to $13.11.

Uranium Resources, Inc. (NASDAQ: URRE) must feel like the Lone Ranger.  It noted, “Tenth Circuit Rules in Favor of Uranium Resources, Inc. in Indian Country Case.”  Only 170,000 shares have traded, but it is up 46% at $0.73 versus a 52-week range of $0.45 to $1.55.

FANNIE MAE & FREDDIE MAC DELISTING

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Sponsor: 26 Cheap Stocks to Sell – Cheap stocks have been on a tear recently, but nine out of ten stocks are circling the drain!

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.